Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Urate lowering treatment"'
Autor:
Wenxuan Liu, Fulong Nan, Fengjun Liu, Xiaoli Yang, Zonghui Li, Shasha Jiang, Xianjuan Zhang, Jun Li, Meng Yu, Yunyang Wang, Bin Wang
Publikováno v:
mSphere, Vol 9, Iss 6 (2024)
ABSTRACT Hyperuricemia has become the second most prevalent metabolic disease after diabetes, but the limitations of urate-lowering treatment (ULT) drugs and patient nonadherence make ULT far less successful. Thus, more ULT approaches urgently need t
Externí odkaz:
https://doaj.org/article/671aa6d8acfe406eab299dfdca8dc7ab
Autor:
Aleš Kvasnička, David Friedecký, Radana Brumarová, Markéta Pavlíková, Kateřina Pavelcová, Jana Mašínová, Lenka Hasíková, Jakub Závada, Karel Pavelka, Pavel Ješina, Blanka Stibůrková
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Currently, it is not possible to predict whether patients with hyperuricemia (HUA) will develop gout and how this progression may be affected by urate-lowering treatment (ULT). Our study aimed to evaluate differences in plasma lip
Externí odkaz:
https://doaj.org/article/31ac9cfa6c504c3cbf5bfdb4c1ca733a
Publikováno v:
Journal of Inflammation Research, Vol Volume 16, Pp 6431-6441 (2023)
Yunyang Wang,1 Jie Lu1– 3 1Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of China; 2Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gou
Externí odkaz:
https://doaj.org/article/56697efe7f2f4076b3f1c1ac8ac30033
Autor:
O. Yu. Mironova
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 72-78 (2022)
The prevalence of hyperuricemia is due to the epidemic of obesity, changes in eating behavior in the population with the rise of purines, alcohol and fructose consumption, as well as the increased use of diuretics. It’s important to mention that ov
Externí odkaz:
https://doaj.org/article/7fdb10de8acd43ab846b4ecc38739c95
Autor:
Till Uhlig, Lars F. Karoliussen, Joe Sexton, Tore K. Kvien, Espen A. Haavardsholm, Fernando Perez-Ruiz, Hilde Berner Hammer
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Objectives To explore the frequency and predictors of flares over 2 years during a treat-to-target strategy with urate-lowering therapy (ULT) in patients with gout. Methods In the treat-to-target, tight control NOR-Gout study patients starte
Externí odkaz:
https://doaj.org/article/1a5f87e14d14442b91f730f8873962a7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nan Liang, Mingshu Sun, Ruixia Sun, Ting Xu, Lingling Cui, Can Wang, Lidan Ma, Xiaoyu Cheng, Xiaomei Xue, Wenyan Sun, Xuan Yuan, Hui Zhang, Hailong Li, Yuwei He, Aichang Ji, Xinjiang Wu, Changgui Li
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Low doses of febuxostat or benzbromarone are widely used in Asian countries, but lacking studies to compare the efficacy and safety of the two urate-lowering drugs. Methods To compare the efficacy and safety of low-dose febuxostat
Externí odkaz:
https://doaj.org/article/694f540010da412f957e8ed9df8bfd28
Autor:
Panagiota Drivelegka, Valgerdur Sigurdardottir, Anna Svärd, Lennart T. H. Jacobsson, Mats Dehlin
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background The aim of this study is to examine the occurrence of comorbidities at the time of first diagnosis of gout compared with matched population controls, overall and by sex, as well as to examine the crude and age-standardized prevale
Externí odkaz:
https://doaj.org/article/73b602b5e3ad4504b823366904a829e1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
Publikováno v:
Journal of Advanced Research, Vol 8, Iss 5, Pp 555-560 (2017)
Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering trea
Externí odkaz:
https://doaj.org/article/d425e0304b3c464390293b68984027d0